Identification and Optimization of 4‐Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase
ChemMedChem2017Vol. 13(1), pp. 48–66
Citations Over TimeTop 10% of 2017 papers
Christopher R. M. Asquith, Tuomo Laitinen, James M. Bennett, Paulo H. Godoi, Michael P. East, Graham J. Tizzard, Lee M. Graves, Gary L. Johnson, Ronna E. Dornsife, Carrow I. Wells, Jonathan M. Elkins, Timothy M. Willson, William J. Zuercher
Abstract
4-Anilinoquinolines were identified as potent and narrow-spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4-anilino group and the 6,7-quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000-fold selectivity relative to other members of the numb-associated kinase (NAK) subfamily, and a compound (6,7-dimethoxy-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine; 49) with a narrow-spectrum kinome profile. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.
Related Papers
- → A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues(2014)53 cited
- → Mapping the Protein Kinome: Current Strategy and Future Direction(2023)5 cited
- → “Going KiNativ”: Probing the Native Kinome(2011)12 cited
- → Abstract B23: Reprogramming of the cancer kinome in response to targeted kinase inhibition(2012)
- → Abstract PO-075: Kinotype to phenotype: Perturbed phosphoproteomic state predicts cancer cell growth rates in vitro(2021)